Augmenting Cerebral Blood Flow to Treat Established Multiple Sclerosis
Status:
Active, not recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
This study will evaluate how improved cerebral blood flow affects the way in which newly
formed MS lesions evolve and whether tissue repair is improved. Patients with multiple
sclerosis (MS) will be treated with acetazolamide in daily divided doses and obtain MRI to
determine how much and in which regions of the brain cerebral perfusion improves as well as
the extent to which tissue integrity is improved in these areas.
Phase:
Phase 2
Details
Lead Sponsor:
The University of Texas Health Science Center, Houston